IN THIS ISSUE: FEATURE: New Drugs in Opiate Addiction Battle. As the overdose statistics continue to rise the need for innovative ways to deal with the Opiate epidemic. Can new drugs be the answer? A look at three promising advances. COMPANY NEWS: OncoSec Advances IL 12 Immunotherpy for Melanoma Interpace Reports Year End Results CymaBay Announces the Retirement of President, CEO, Harold Van Wart, Ph.D. ITUS closes $4.7 Million Rights offering INTERVIEWS: Glynn Wilson, CEO of TapImmune on cancer treatment David Buzkin, head of Marcum’s SEC practice on IPO trends IDEAS & TECHNOLOGIES: Sensori AB- Medical Devices for the Human Senses with Common Sense…
Author: The Sentinel
Leap Therapeutics, Inc. (LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, recently reported financial results for the year ended December 31, 2016 and top-line progression-free survival (PFS) data. Earlier this year, Leap merged with Macrocure Ltd. and became listed on NASDAQ. The company’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with gastroesophageal cancer in combination with paclitaxel and in patients with biliary tract cancers in combination with gemcitabine and cisplatin. DKN-01 has demonstrated single agent activity in non-small cell lung cancer patients. Leap’s second clinical candidate, TRX518,…
Genprex is a clinical-stage biopharmaceutical company developing targeted molecular therapies for cancer. The company is developing molecular therapies that control universal cancer pathways to unlock the unrealized potential of targeted cancer therapies, such as tyrosine kinase inhibitory drugs (TKIs). Genprex’s tumor suppression technologies are pan-kinase inhibitors that work to induce apoptosis (programmed cell death) in cancer cells and to control cell signaling and inflammatory pathways to treat cancer at the molecular level. Their discoveries and R&D programs have been the subject of more than 30 peer-reviewed publications and have been supported by corporate investment and grants from the NIH, SBIR, U.S. Department of…
Immunotherapy is the future of cancer treatment and TapImmune has been leading the charge. CEO Glynn Wilson discusses the advances made in the ovarian and breast cancer. The company is taking a vaccine approach to reduce recurrence of cancer and to improve progression free survival and in some cases to treat cancers that couldn’t otherwise be treated. Brett Johnson: What does TapImmune do? What is your mission? Glynn Wilson: TapImmune is an immuno-oncology company focusing on women’s cancers. The aim of the company is to broadly activate T-cells to recognize and kill specific cancer targets in addition to improving antigen…
OncoSec Medical Incorporated (NASDAQ: ONCS) was recently granted FDA Fast Track designation to address the large population of non-responders to the current leading checkpoint inhibitor therapies for stage 4 melanoma. The leading drugs in this $5 billion market are marketed under the names, Opdivo and Keytruda. An estimated 70% of patients do not respond to these checkpoint therapies. OncoSec has shown data indicating that when used with their technology ImmunoPulse IL-12, there is a 48% response in this non-responder patient population. Approximately 10,000 patients each year could be candidates for OncoSec’s ImmunoPulse IL-12 when used in combination with Opdivo…
Interested in joining the OneMedNews team? See below for open job opportunities. Journalism/Public Relations freelance writer OneMedNews is looking for a go-getter freelance writer to conduct interviews and write stories for the OneMedNews Sentinel, a biweekly e-newsletter focused on the healthcare and life sciences industry. Must be interested in covering healthcare, finance and biotech. Will also help with marketing and other writing, editing and administrative tasks for various projects and healthcare investment events that the company is involved in throughout the year. The best candidate will have experience and an interest in networking and attending various healthcare conferences in order to get…
IN THIS ISSUE: FEATURE: The Case for a Healthcare Futures Market Dennis Purcell and his team at Poliwogg outline the prospects and potential to bring stability to the healthcare market through creating a futures exchange, starting with a diabetes index. COMPANY NEWS: Life Care Medical Devices adds prominent industry expert and investor to board Neurotrope advances Phase 2 Alzheimer’s trial Lattice Biologics reports Q1 highlights and progress on new osteoarthritis treatment INTERVIEWS: Kevin Connolly, CEO of Vesiflo on the $1 billion catheter market Richard Daly, CEO of Neuralstem on major depressive disorder Christopher Schaber PhD, CEO of Soligenix on orphan…
OmniCyte Founder, Peter Leonardi, provides insight into the emerging field of immunotherapy. Immunotherapy is the process that uses the body’s natural defense system to cure cancer. The most popular area is in checkpoint inhibitors, which remove the blockade that defends the cancer cells from the body’s natural defenses. Brett Johnson interviews Dr. Leonardi to discuss OmniCyte’s emerging technique that involves the enhancement of the body’s ability to attack cancer. Brett Johnson: Cancer immunotherapy has become a very exciting area both in general and for investors. What is cancer immunotherapy? Peter Leonardi: Cancer immunotherapy, or immune-oncology, is the use of the body’s…